Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Eur J Clin Microbiol Infect Dis ; 43(7): 1475-1480, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38753112

ABSTRACT

Implant-related infections may need suppressive antibiotic therapy (SAT). We describe a SAT strategy using dalbavancin with therapeutic drug monitoring (TDM). This is a retrospective bicentric study of patients with implant-related infection who received dalbavancin SAT between January 2021 and September 2023. Fifteen patients were included. Median number of injections was 4 (IQR: 2-7). Median time between two reinjections was 57 days (IQR 28-82). Dalbavancin plasma concentrations were above 4 mg/L for 97.9% of dosages (93/95) and above 8 mg/L for 85% (81/95). These results support the use of dalbavancin SAT for implant-related infections.


Subject(s)
Anti-Bacterial Agents , Drug Monitoring , Prosthesis-Related Infections , Teicoplanin , Humans , Teicoplanin/analogs & derivatives , Teicoplanin/therapeutic use , Teicoplanin/administration & dosage , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/administration & dosage , Retrospective Studies , Male , Aged , Female , Middle Aged , Prosthesis-Related Infections/drug therapy , Aged, 80 and over
SELECTION OF CITATIONS
SEARCH DETAIL
...